US legal appeal rejected in win for Novo Nordisk

A US court has rejected an appeal attempting to overturn a ruling that Novo Nordisk’s type 2 diabetes drug, Victoza, does not cause cancer.

Photo: Novo Nordisk / PR

The 9th US Circuit Court of Appeals voted unanimously on Monday to reject an attempt to reopen a legal case against Novo Nordisk, reports Reuters. The case concerned its type 2 diabetes drug Victoza, which the plaintiff claimed could cause pancreatic cancer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs